Financhill
Buy
67

GNGBF Quote, Financials, Valuation and Earnings

Last price:
$23.23
Seasonality move :
-1.53%
Day range:
$23.23 - $23.23
52-week range:
$18.82 - $24.75
Dividend yield:
2.04%
P/E ratio:
27.03x
P/S ratio:
1.77x
P/B ratio:
1.98x
Volume:
--
Avg. volume:
1.1K
1-year change:
10.04%
Market cap:
$6.3B
Revenue:
$3.6B
EPS (TTM):
$0.86

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Getinge AB has -- downside to fair value with a price target of -- per share.

GNGBF vs. S&P 500

  • Over the past 5 trading days, Getinge AB has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Getinge AB does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Getinge AB has grown year-over-year revenues for 12 quarters straight. In the most recent quarter Getinge AB reported revenues of $1.1B.

Earnings Growth

  • Getinge AB has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Getinge AB reported earnings per share of $0.34.
Enterprise value:
7.1B
EV / Invested capital:
--
Price / LTM sales:
1.77x
EV / EBIT:
15.19x
EV / Revenue:
2.00x
PEG ratio (5yr expected):
0.52x
EV / Free cash flow:
25.51x
Price / Operating cash flow:
22.58x
Enterprise value / EBITDA:
10.41x
Gross Profit (TTM):
$1.6B
Return On Assets:
3.88%
Net Income Margin (TTM):
6.59%
Return On Equity:
7.64%
Return On Invested Capital:
5.59%
Operating Margin:
15.35%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-31 2024-12-31 2025-12-31 2024-12-31 2025-12-31
Income Statement
Revenue $3B $3.3B $3.6B $1B $1.1B
Gross Profit $1.3B $1.4B $1.6B $435.6M $478.1M
Operating Income $340.8M $384.9M $470.5M $153M $166.2M
EBITDA $533.7M $583M $686.7M $209.5M $223.7M
Diluted EPS $0.83 $0.57 $0.86 $0.23 $0.34
Period Ending 2021-12-31 2022-12-31 2023-12-31 2024-12-31 2025-12-31
Balance Sheet
Current Assets $1.7B $1.8B $1.7B $1.6B $1.9B
Total Assets $4.9B $5.1B $5.5B $6B $6.5B
Current Liabilities $264.6M $1.2B $1.3B $1.4B $1.4B
Total Liabilities $2.1B $2.2B $2.5B $3B $3.3B
Total Equity $2.8B $2.9B $3B $3B $3.2B
Total Debt $423.1M $519.6M $534M $793.8M $1B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-31 2024-12-31 2025-12-31 2024-12-31 2025-12-31
Cash Flow Statement
Cash Flow Operations $275.3M $423.4M $419.9M $181.1M $168.2M
Cash From Investing -$614.3M -$420.7M -$314.8M -$34.9M -$50.6M
Cash From Financing $47.3M $49.3M -$81.3M -$51.4M -$66.6M
Free Cash Flow $147.9M $302.7M $280.2M $151.4M $127.7M
GNGBF
Sector
Market Cap
$6.3B
$23.9M
Price % of 52-Week High
93.86%
47.44%
Dividend Yield
2.04%
0%
Shareholder Yield
1.79%
-1.88%
1-Year Price Total Return
10.04%
-18.29%
Beta (5-Year)
0.726
0.513
Dividend yield:
2.04%
Annualized payout:
$0.47
Payout ratio:
149.04%
Growth streak:
1 years

Technicals

8-day SMA
Sell
Level $23.23
200-day SMA
Buy
Level $21.84
Bollinger Bands (100)
Buy
Level 21.46 - 24.16
Chaikin Money Flow
Sell
Level --
20-day SMA
Sell
Level $23.23
Relative Strength Index (RSI14)
Sell
Level 27.84
ADX Line
Neutral
Level
Williams %R
Buy
Level -100
50-day SMA
Sell
Level $23.63
MACD (12, 26)
Buy
Level 5.18
25-day Aroon Oscillator
Sell
Level 0
On Balance Volume
Neutral
Level --

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.466)
Buy
CA Score (Annual)
Level (0.0774)
Buy
Beneish M-Score (Annual)
Level (-2.5542)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-0.6671)
Buy
Piotroski F Score (Annual)
Level (7)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (10)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Getinge AB is a medical technology company specializes in providing equipment, systems, operating rooms, intensive-care units to the healthcare and the life science industries. It offers products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. The firm operates through the following segments: Acute Care Therapies, Life Science and Surgical Workflows. The Acute Care Therapies segment offers solutions for life support in acute health conditions. The Life Science segment offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in biopharmaceutical production, biomedical research, medical device manufacturing and laboratory applications. The Surgical Workflows segment offers products and services for efficient disinfection and sterilization of instruments used in operations, operating tables and other high-quality hardware for operating rooms and advanced IT systems for efficient and secure hospital workflows. The company was founded by Olander Larsson in 1904 and is headquartered in Gothenburg, Sweden.

Stock Forecast FAQ

In the current month, GNGBF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GNGBF average analyst price target in the past 3 months is --.

  • Where Will Getinge AB Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Getinge AB share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About Getinge AB?

    Analysts are divided on their view about Getinge AB share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Getinge AB is a Sell and believe this share price will rise from its current level to --.

  • What Is Getinge AB's Price Target?

    The price target for Getinge AB over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is GNGBF A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Getinge AB is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of GNGBF?

    You can purchase shares of Getinge AB via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Getinge AB shares.

  • What Is The Getinge AB Share Price Today?

    Getinge AB was last trading at $23.23 per share. This represents the most recent stock quote for Getinge AB. Yesterday, Getinge AB closed at $23.23 per share.

  • How To Buy Getinge AB Stock Online?

    In order to purchase Getinge AB stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Celestica The Best AI Stock to Buy Now?
Is Celestica The Best AI Stock to Buy Now?

Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…

Will AI Disrupt SaaS Software Stocks?
Will AI Disrupt SaaS Software Stocks?

Since January 28th, software stocks in the United States have…

Why Is Meta Stock Going Higher?
Why Is Meta Stock Going Higher?

Over the last five days, shares of Instagram and Facebook…

Stock Ideas

Sell
46
Is NVDA Stock a Buy?

Market Cap: $4.3T
P/E Ratio: 36x

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 34x

Sell
40
Is GOOGL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 27x

Alerts

Buy
51
AAOI alert for Apr 3

Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.

Buy
59
SBAC alert for Apr 3

SBA Communications Corp. [SBAC] is up 18.96% over the past day.

Buy
55
VSAT alert for Apr 3

ViaSat, Inc. [VSAT] is up 18.73% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock